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African trypanosomosis is a debilitating disease of great medical and socioeconomical 
importance. It is caused by strictly extracellular protozoan parasites capable of infecting 
all vertebrate classes including human, livestock, and game animals. To survive within 
their mammalian host, trypanosomes have evolved efficient immune escape mecha-
nisms and manipulate the entire host immune response, including the humoral response. 
This report provides an overview of how trypanosomes initially trigger and subsequently 
undermine the development of an effective host antibody response. Indeed, results 
available to date obtained in both natural and experimental infection models show 
that trypanosomes impair homeostatic B-cell lymphopoiesis, B-cell maturation and 
survival and B-cell memory development. Data on B-cell dysfunctioning in correlation 
with parasite virulence and trypanosome-mediated inflammation will be discussed, as 
well as the impact of trypanosomosis on heterologous vaccine efficacy and diagnosis. 
Therefore, new strategies aiming at enhancing vaccination efficacy could benefit from a 
combination of (i) early parasite diagnosis, (ii) anti-trypanosome (drugs) treatment, and 
(iii) anti-inflammatory treatment that collectively might allow B-cell recovery and improve 
vaccination.
Keywords: B-cell lymphopoiesis, African trypanosomosis, vaccination strategies, inflammation, T-cells, 
macrophage migration inhibitory factor (MiF)
iNTRODUCTiON
African trypanosomes are strictly extracellular single-celled protozoan parasites belonging to the 
genus Trypanosoma, which cause debilitating diseases in humans and livestock and consequently 
significantly affect the socioeconomic development of sub-Saharan Africa (1). About 70 million 
people distributed over a surface of one and a half million square kilometers are estimated to be 
at risk for contracting sleeping sickness in Africa (2). The distribution of African trypanosomes 
coincides mostly with the distribution of the habitat of the hematophagic insect vector, i.e., the tsetse 
“fly” (Glossina sp.), with tsetse meaning “fly” in the Tswana language of Southern Africa (3). Human 
African trypanosomosis (HAT) or sleeping sickness is caused by Trypanosoma brucei gambiense 
(west and central Africa) and Trypanosoma brucei rhodesiense (eastern and southern Africa) (4, 5). 
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Both parasites cause infections that exhibit clinically diverse 
patterns and hence require different patient management, with 
the less prevalent T. b. rhodesiense HAT considered to be the 
more acute and virulent/lethal form of the disease (6, 7). HAT 
mainly affects remote rural communities where the health 
infrastructure is often minimal. In general, the disease is char-
acterized by two stages: the early hemolymphatic stage whereby 
parasites proliferate in the blood and lymphatic system and the 
late meningoencephalitic stage whereby parasites penetrate the 
blood–brain barrier and proliferate in the cerebral spinal fluid 
(8). When patients in the meningoencephalitic stage remain 
untreated, an encephalitic reaction can occur resulting in coma 
and subsequent death (9–11). However, it is important to men-
tion that in recent years a number of reports have indicated 
that HAT is not always lethal and that both T. b. gambiense and 
T. b. rhodesiense can result in chronic human infections with 
little or no symptoms (12, 13). Limited surveillance in particular 
of non-symptomatic cases, however, make it hard to assess how 
widespread these non-lethal cases are, or what the molecular and 
genetic underlying factors are that account for HAT resistance in 
certain individuals (14).
According to WHO, recent successes in the fight against HAT 
have brought the annual new cases to less than 10,000 (5, 7, 8). 
To design and maintain future control strategies, it is important 
to indicate that T. b. gambiense is an anthroponotic disease with 
a minor role for animal reservoirs that accounts for 98% of the 
reported HAT cases and causes a chronic, gradually progress-
ing disease, whereby the late meningoencephalitic stage is not 
reached before months or even years of infection (10, 15). T. 
b. rhodesiense on the other hand is a zoonotic disease affecting 
mainly animals (livestock and wildlife), with humans being only 
accidentally infected, and represents only 2% of the reported 
HAT cases, whereby the infections are acute and progress rapidly 
(within weeks) to the late meningoencephalitic stage (10, 16). 
The zoonotic nature of T. b. rhodesiense infections make them 
more difficult to control compared to T. b. gambiense infections 
(15, 17, 18). Animal African trypanosomosis (AAT) also known 
as Nagana is a second form of trypanosomosis that affects sub-
Saharan Africa. It is mainly caused by Trypanosoma congolense, 
Trypanosoma vivax, and to a lesser extent Trypanosoma brucei 
brucei, while surra and dourine are also forms of AAT caused by 
Trypanosoma evansi and Trypanosoma equiperdum, respectively 
(19–21). Of note, some parasites acquired a mechanical trans-
mission mode (hence, they can reside outside the tsetse/vector 
belt) and are also found in South/Latin America (T. vivax and 
T. evansi) and Asia (T. evansi and T. equiperdum) (19, 21–23). Yet, 
T. congolense forms a major constraint on livestock production 
and remains the leading cause of livestock morbidity and mortal-
ity in sub-Saharan Africa. Hereby, cattle succumb to infection 
primarily due to parasite-induced anemia or complications result-
ing from secondary, opportunistic infections (24). Progressive 
disease for a prolonged time will weaken these animals, thereby 
preventing them to be used as draft animals or for food/milk 
production. As a result, farming in the tsetse belt remains chal-
lenging and hampers the development of poor societies, lead-
ing to great economic losses in terms of productivity (25, 26). 
Indeed, AAT accounts for an estimated annual loss of about 
US$5 billion, whereby Africa invests every year at least US$30 
million to control cattle trypanosomosis in term of curative and 
prophylactic treatments (27, 28). The total losses for the total tsetse-
infested lands in terms of agricultural gross domestic product are 
US$4.75 billion per year (1). In fact, the impact of AAT on the 
affected areas is the combined result of environmental, political, 
sociocultural, entomological, and livestock management factors 
(29), whereby (i) the political instability of the areas hampers 
controlled intervention strategies and subsequently discourages 
commercial investment in control strategies, (ii) pharmaceutical 
companies are less prone to engage/invest in drug discovery/
development against diseases that affect the poorest people, (iii) 
wild animals function as reservoir of the parasite and therefore 
hamper the control of the disease, and (iv) the inappropriate 
use of the available drugs resulting in the emergence of drug 
resistance (30, 31). Up till now, not a single-field applicable 
vaccine exists, and chemotherapy is the only strategy available 
to treat the disease, which is associated with high drug toxicity. 
Nevertheless, so far chemotherapy remains the only therapeutic 
choice for these diseases, whereby they target unique organelles 
of trypanosomes such as glycosomes and the kinetoplast that 
are absent in the mammalian host or trypanosome metabolic 
pathways that differ from the host counterparts [carbohydrate 
metabolism, protein and lipid modifications, and programmed 
cell death (PCD)] (32–34). Unlike the situation with HAT, where 
the nifurtimox–eflornithine combination therapy is the preferred 
first-line treatment for second-stage disease (35, 36), no drug 
combinations are currently used for AAT (27). Instead, alternating 
use of compounds, particularly diminazene and isometamidium 
(called a “sanative pair”), with low risk of cross-resistance, is 
recommended where possible. Hence, there is an urgent need to 
optimize trypanocide usage/delivery such as extending the half-
life of current trypanocides to use lower quantities of trypanocide 
in a more effective way and, consequently, pose a decreased risk 
of toxicity and possibly decreased resistance development (37, 
38). However, there is some optimism since progress in HAT/
AAT control measures were made over the past decade due to 
the establishment of the Pan-African tsetse and trypanosome 
eradication campaign, funded by the African Development Bank, 
which was established in the year 2000. This organization has 
set tsetse elimination as its goal and has strengthened renewed 
interest in the research and development of control/intervention 
options (29, 39). Overall, “elimination” of T. b. gambiense HAT 
has been targeted for 2020 under leadership of the WHO (40).
One crucial factor that stands in the way of total eradication of 
trypanosomosis in general is inefficient diagnosis of the infection. 
To date, microscopy detection of the parasite remains the only 
available tool to diagnose AAT and T. b. rhodesiense HAT in a 
reliable way. Only for T. b. gambiense, monitoring tools are avail-
able for both detection of exposure and staging of the disease (41). 
The latter is important to reduce the risk of treatment-associated 
complications occurring during treatment of the second stage of 
the disease (42). In this context, improvement in staging diagnosis 
and early screening methods are current challenges, which would 
avoid delayed patient treatment. Diagnosis is often hampered due 
to lack of positive predictive value of existing field applicable tech-
niques and the fact that antibody (Ab)-based detection cannot 
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differentiate between active or passed—but cured—infections 
(41). Immunodiagnostics based on antigen detection in this case 
would be preferable but are currently non-existent for trypano-
somosis in the field (41, 43). An additional complication resides 
in the recent finding that tsetse-transmissible T. b. gambiense 
parasites can be found in human skin biopsies from undiagnosed 
individuals (44). Hence, this suggests that the current diagnostic 
methods and control policies need to be reevaluated.
In the next sections, we will give an overview of (i) the differ-
ent escape mechanisms used by African trypanosomes to survive 
within their mammalian host and (ii) their strategies to undermine 
the entire host immune response, including the humoral response, 
which in turn hampers vaccine development. This review will focus 
on two most relevant AAT species T. brucei and T. congolense, 
given that for both parasites, established murine models and field 
studies in the economically and clinically relevant host (cattle) are 
available (45). While for T. vivax, field study information is scanty, 
hardly any representative experimental data are available as these 
parasites do not grow in mice unless they are carefully adapted 
(23, 46, 47). However, there is prospect since Minoprio and 
coworkers were able to establish a murine model for T. vivax 
(48). Although rodents are not natural hosts for these pathogens, 
murine models can be considered valuable tools to unravel the 
interactions and the immune evasion mechanisms of these para-
sites with their mammalian host.
HOST–PARASiTe iNTeRACTiONS
Life Cycle of African Trypanosomes
African trypanosomes have a digenetic/heteroxenous complex 
life cycle alternating between the intestine of the tsetse fly vec-
tor and the blood/tissues of the mammalian host, whereby they 
progress through different developmental stages, i.e., procyclic 
or trypomastigote forms, respectively (49, 50). Yet, to survive in 
each of these hosts, they undergo essential changes at the level 
of morphology, energy metabolism, and surface coat protein 
expression (51, 52). Hereby, trypanosomes feed by absorbing 
nutrients (proteins, carbohydrates, and fats) as well as iron and 
oxygen from the body fluids of the host to generate the energy 
necessary for the vital processes (53). Within the bloodstream of 
the mammalian host, they subsist as bloodstream forms (BSFs) 
that are ingested by tsetse flies during a blood meal, wherein they 
differentiate into procyclic forms in the insect midgut. Next, they 
migrate to the proboscis (mouth parts) where they differentiate 
into epimastigote forms and finally into infective metacyclic 
forms (MCFs) that can be transmitted to a new mammalian host 
during the next blood meal. Although within the tsetse fly both 
T. brucei and T. congolense parasites have a similar migratory life 
cycle (i.e., initial establishment of midgut infection and invasion 
of the proventriculus), they exhibit differences in transitional 
developmental stages with production of infective MCFs in 
the proboscis for T. congolense and in the salivary glands for 
T. brucei (54–56). Within the mammalian host, T. congolense is 
a strictly intravascular parasite, whereby they bind to circulating 
erythrocytes and endothelial cells through their flagellum, caus-
ing damage at the adhesion site (57, 58). In contrast, T. brucei can 
also extravasate blood vessels and invade tissues and cause severe 
tissue injury (44, 59, 60). Hence, this implies differences in viru-
lence mechanisms, host–pathogen relationships, and pathogenic 
effects between the two species (61). In addition, T. congolense 
exists strictly as a long slender (LS) dividing form, whereas 
T. brucei parasites are pleomorphic (i.e., can exhibit two forms); 
a LS dividing form and a short stumpy (SS) non-dividing form 
that is preadapted for transmission to the fly (62, 63). This transi-
tion, which involves a quorum sensing factor (i.e., an enigmatic 
stumpy inducing factor), is suggested to help control parasitemia 
and to increase the host survival time, thereby increasing the 
probability for successful transmission of the trypanosomes to a 
new host (50, 64). It is suggested that this removal of the majority 
of the population is an altruistic form of PCD and the counterpart 
of apoptosis in metazoan (65, 66). Hereby, increased intracellular 
reactive oxygen species and prostaglandin D2, which is produced 
principally by stumpy forms, are promoting this PCD that can be 
considered as a second control point in terminal differentiation 
to the SS form (67, 68). Moreover, it is suggested that the SS form 
is heterogeneous, whereby one part is altruistic and undergoes 
apoptosis-like events, thereby stimulating the host’s immune 
response and eliminating the major LS and SS antigen popula-
tion, while the other is tsetse infective (69). Both the LS and SS 
forms are covered by a dense variant surface glycoprotein (VSG) 
coat, which protects them from both the innate and the adaptive 
host immune systems. Of note, within the tsetse fly, the parasites 
are covered by a procyclin coat, and only when they differentiate 
into the MCF (infective form), they express a metacyclic VSG 
coat (70).
Parasite escape Mechanisms  
in the Mammalian Host
To survive as extracellular parasites within the mammalian 
host environment (i.e., blood or extravascular tissues), African 
trypanosomes have developed efficient immune evasion mecha-
nisms, at both the parasite level and the level of modulating host 
responses. Indeed, during millions of years of coevolution with 
their mammalian host, these parasites have “learned” to divert and 
sculpture the host immune system to prevent the generation of 
an effective response. The most predominant changes at the level 
of the host occurring during African trypanosomosis are mas-
sive splenomegaly coinciding with destruction of the lymphoid 
architecture and hepatomegaly. These modulations are followed 
by lymphadenopathy and hypergammaglobulinemia, leading to 
systemic multiple organ failure and death in experimental mouse 
models (71). In this section, we will give an overview of the most 
prominent escape mechanisms trypanosomes developed to allow 
successful infection within their mammalian host.
Parasite-Associated Escape Mechanisms
Already at the onset of infection, i.e., inoculation of trypanosome-
containing saliva upon the bite of a tsetse fly, components present 
in the saliva are able to (i) dampen local host inflammatory 
immune responses characterized by the release of trypanolytic 
molecules, i.e., tumor necrosis factor (TNF) and nitric oxide 
(NO), thereby favoring parasite development and (ii) trigger mast 
FigURe 1 | Model for African trypanosomosis within the mammalian host. (1) Upon the bite of a trypanosome-infected tsetse fly, metacyclic form (MCF) 
parasites are inoculated within the mammalian host. (2) These parasites differentiate into bloodstream forms (BSFs) and switch their metacyclic VSG (M-VSG) into a 
bloodstream uniform VSG (VSG1) giving rise to the first parasitemia peak. During the course of infection, there is antigenic variation (VSG2, VSG3, etc.) giving rise to 
different peaks of parasitemia. (3,4) Parasites-derived components trigger B-cell activation and production of antiparasite IgG needed for parasitemia control. (5,6) 
Parasite-derived components trigger NK, NKT, and T-cell activation resulting in the production of interferon-gamma (IFN-γ). (7) Parasite-derived components in 
concert with IFN-γ trigger the induction of classically activated macrophages (M1 cells). (8) These M1 cells release pro-inflammatory cytokines [like tumor necrosis 
factor (TNF)] that are needed for parasite control, but at the same time contribute to pathology development if maintained during the course of infection.
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cell degranulation resulting in release of histamine and increased 
vasodilatation, thereby allowing parasite dissemination/extrava-
sation into the blood circulation [reviewed in Stijlemans et  al. 
(72)]. Within the mammalian host, trypanosomes are very profi-
cient in avoiding and subsequently reorchestrating host immune 
responses. Being extracellular parasites, they are confronted with 
the host’s humoral immune response; hence, to allow infection to 
occur, they have to overcome this major obstacle. In first instance, 
these parasites are covered with a very dense coat composed of 
approximately 5 × 106 identical VSG homodimers of 50–60 kDa 
subunits that are anchored in the plasma membrane by a gly-
cosylphosphatidylinositol (GPI) anchor, which functions as a 
~15-nm thick barrier and protects the cell from Abs that might 
bind to buried conserved proteins (73, 74). Second, to prevent 
Ab-mediated elimination by Abs raised against the immuno-
dominant/immunogenic VSGs, these parasites acquired a system 
of antigenic variation, whereby they are equipped with a battery 
of more than 1,000 different VSG genes and pseudogenes in their 
genome that in turn can undergo segmental gene recombination 
to encode an estimated 10,000 different VSG surface coats during 
infection (75). Hence, at regular time points [i.e., upon recogni-
tion by the host’s humoral response or when a maximal density is 
reached (Quorum sensing)], they switch their coat into a different 
variable antigen type, thereby allowing escaping Ab-mediated 
elimination (76). This antigenic variation is accomplished by (i) 
in situ switching of transcriptional control (i.e., changing the VSG 
expression site) or (ii) gene replacement resulting in a switch of 
the terminal telomeric VSG gene itself (77, 78). Besides antigenic 
variation, these parasites were shown to express a mosaic VSG 
during the process of VSG switching (i.e., changing from meta-
cyclic to BSFs, or during the course of infection), which in turn 
might be an efficient way to prevent effective Ab recognition (79, 
80). Also the infective MCFs use this differential VSG expres-
sion to generate diversity and counter existing partial immunity/
enhance transmission, while BSF use this to prolong infection 
(see Figure 1). Interestingly, the MCFs initiate VSG expression 
by each cell, activating at random one from a small subset of 
metacyclic VSG (M-VSG) genes, resulting in a heterogenous 
population, whereby each trypanosome expresses a single VSG 
(81, 82). Hereby, the M-VSG expression is regulated exclusively at 
the transcriptional level, while the bloodstream VSG expression 
is regulated mainly at the posttranscriptional levels and tran-
scribed polycistronically (83). Third, trypanosomes also exhibit a 
very high endocytosis rate as an efficient way to acquire nutrients 
and at the same time to remove Ab-bound VSG molecules and 
thereby prevent Ab-mediated or even complement-mediated 
opsonization/elimination (84, 85). This might allow parasites 
to transiently escape T-cell-independent B-cell-mediated 
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elimination, which is the first line of defense. This immunological 
escape also gives time to transform into trypomastigote forms, 
which are adapted to survive in the mammalian host during the 
initiation of infection and gives the parasites an immunological 
advantage during the process of antigenic variation.
Although mainly IgMs play a key role during T. brucei infec-
tion, while in T. congolense infections, IgGs are mostly important 
(86, 87), it could be assumed that complement-mediated lysis 
is also an important innate defense mechanism. However, 
trypanosomes have developed efficient mechanisms to avoid 
complement-mediated elimination. First, trypanosomes are 
able to avoid elimination via the complement pathway, which 
is typically activated via immune complexes with Abs. Indeed, 
by releasing vast amounts of soluble VSG (mainly at the peak of 
parasitemia), Abs and complement factors will be scavenged and 
thereby induce a state of hypocomplementemia that can favor the 
survival of the parasites (88). Second, besides undermining the 
classical activation of the complement pathway that could contrib-
ute to trypanosome clearance through Ab-mediated trypanolysis 
and/or phagocytosis, the alternative pathway of complement 
activation occurring in the absence of specific Abs (i.e., during 
early stages of infection) is also impaired. Indeed, by masking 
sites on the VSG plasma membrane, which are capable of pro-
moting alternative pathway activation, the cascade is blocked at 
the C3 convertase stage, thereby impairing the generation of the 
terminal complex (C5–C9) that normally induces trypanolysis 
(89, 90). However, it seems that the later stages of the complement 
activation cascade do not play a detrimental role in parasite con-
trol. Indeed, in AKR mice, which are natural C5 KO mice (91), 
the absence of the complement lysis pathway does not prevent 
periodic trypanosome clearance and does not hamper long-term 
survival in case of T. congolense infections (92, 93). However, 
soluble complement molecules, such as C3a and C5a, secreted 
during early stages of trypanosome infection, can contribute to 
the initiation of the early inflammatory immune response and 
also act as (i) chemotactic agents attracting phagocytes to the site 
of infection and (ii) release histamine from mast cells, thereby 
increasing microvascular permeability (94), which would allow/
enable parasite extravasation into the blood circulation.
Parasite-Induced Escape Mechanisms
Besides being equipped with tools to avoid elimination by the 
host’s “innate” humoral response, trypanosomes also undermine 
the host cellular immune responses to allow chronic infection. 
Moreover, the data in literature suggest that the efficiency to 
modulate the innate immune response is crucial for the progres-
sion of trypanosomosis (95). Hereby, the suppression of cellular 
immune responses is an efficient mechanism to evade host 
defense mechanisms and a general feature of trypanosomosis in 
bovine, human, and murine hosts. To this end, these parasites 
are equipped with a battery of molecules able to modulate early 
antiparasite responses to allow establishment. It is important to 
mention that the course of an African trypanosome infection 
can be characterized by an early release of interferon-gamma 
(IFN-γ) by activated NK-, NKT- and T-cells required to induce 
classically activated macrophages (M1) (see Figure 1). In turn, 
these activated M1 develop upon exposure to parasite-derived 
molecules such as VSG and CpG a type-1 inflammatory immune 
response leading to the production of the potential trypanocidal 
molecules such as TNF and NO that in conjunction with Abs 
will contribute to parasite control (96, 97). Yet, persistence of 
this type-1 immune response and hyperactivated M1 cells will 
culminate in trypanosusceptible animals into immunopathologi-
cal features such as the systemic immune response syndrome and 
anemia (98). Trypanotolerant animals on the other hand are able 
to switch to a more type-2 immune response and the induction 
of alternatively activate macrophages (M2), whereby the anti-
inflammatory cytokine interleukin (IL)-10 was shown to play a 
pivotal “dampening” role (99, 100).
Undermining Macrophage Functionality
To sustain the development of the first (most prominent) peak 
of parasitemia in the blood and its control by the host, some 
parasite-derived molecules are able to dampen pro-inflammatory 
responses (TNF, NO) by these M1. Most research so far has been 
performed using T. brucei infections and indicate that these 
parasites release components such as adenylate cyclase (AdC) 
and kinesin heavy chain (TbKHC-1) to dampen initial host 
responses, thereby allowing early parasite establishment (101, 
102). Indeed, AdC released by altruistic parasites upon parasite 
phagocytosis by liver-associated myeloid cells prevents produc-
tion of the trypanolytic cytokine TNF (via a protein kinase A 
pathway), which promotes early establishment of trypanosomes 
within the mammalian host (101). On the other hand, the release 
of TbKHC-1 by parasites induces IL-10 and arginase release by 
myeloid cells in a SIGN-R1-dependent manner and favors initial 
parasite seeding by inducing the production of polyamines, which 
constitute trypanosome essential nutrients (102, 103). Recently, it 
was also shown that metabolites produced by trypanosomes such 
as indolepyruvate (i.e., a transamination product of tryptophan) 
can dampen macrophage pro-inflammatory responses that pre-
vent elimination (104). Finally, the order of exposure to parasite-
derived versus host-derived macrophage-activating components 
as well as the relative concentration of these mediators may 
influence the ability of the host to respond to trypanosome infec-
tions. Indeed, early during infection, exposure of macrophages 
to soluble VSG (encompassing the glycosylinositolphosphate 
substituent) before IFN-γ priming downregulated the level of 
signal transducer and activator of transcription 1 phosphoryla-
tion, which in turn reduced transcription of pro-inflammatory 
cytokines such as TNF (105). So far, nothing is known about 
such mechanisms for T. congolense. In summary, it seems that 
trypanosomes have developed a system whereby altruistic 
parasites are phagocytosed, thereby disabling the M1-mediated 
innate immune response required for parasite control and pav-
ing the way for initiation and establishment of the first wave of 
parasitemia.
Modulation of T-Cell Functionality
Besides undermining the antitrypanosomal potential of the 
myeloid system, the parasite is also impairing T-cell help required 
to mount a more efficient response during the course of infection. 
Early during T. brucei and T. congolense infection, T-cell sup-
pression is occurring via suppressive myeloid cells by inhibiting 
TABLe 1 | B-cell surface marker expression used to track cellular alterations during infection.
Marker expression
Hematopoietic stem cell (Lin−) (Terll9, CD3, CDllb, GR1, NK1.1)−, B220+, CD93+, IL7r, ckit+, CD34+
Common lymphoid progenitor (Lin−) (Ter119, CD3, CD11b, GR1, NK1.1)−, B220+, CD93+, IL7r+, ckit+, CD34−
Pre-proB (Lin−) (Ter119, CD3, CD11b, GR1, NK1.1)−, B220+, CD93+, CD19−, IgM−, CD43high
ProB (Lin−) (Ter119, CD3, CD11b, GR1, NK1.1)−, B220+, CD93+, CD19+, IgM−, CD43high
PreB (Lin−) (Ter119, CD3, CD11b, GR1, NK1.1)−, B220+, CD93+, CD19+, IgM−, CD43low/−
Immature B (BM) (Lin−) (Ter119, CD3, CD11b, GR1, NK1.1)−, B220+, CD93+, CD19+, IgM+, CD43low/−
Transitional B (Lin−) (blood/spleen) (Ter119, CD3, CD11b, GR1, NK1.1)−, B220+, CD93+, CD19+, IgM+, IgD+, CD21+
Immature B (spleen) (Lin−) (Ter119, CD3, CD11b, GR1, NK1.1)−, B220+, CD93+, CD19+, IgM+, IgD+, CD21+
Mature B (Ter119, CD3, CD11b, GR1, NK1.1)−, B220+, CD93−, CD19+, IgM+, IgD+, CD21+
Marginal zone B (Ter119, CD3, CD11b, GR1, NK1.1)−, B220+, CD93−, CD19+, IgM+, IgD+, CD21+, CD1dhigh
Follicular B (Ter119, CD3, CD11b, GR1, NK1.1)−, B220+, CD93−, CD19+, IgM+, IgD+, CD21+, CD1d−
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IL-2 secretion and downregulation of IL-2 receptor expression 
(106–108), whereby prostaglandins were found to play an impor-
tant role in the murine model, but not in the bovine model (109). 
In addition, early data on T cell regulation and trypanosomosis 
showed that both IFN-γ and TNF play a key role in the suppres-
sive effects on CD4 and CD8 T-cells (107). Furthermore, this 
suppressive phenotype of the host cells during the early stages of 
T. brucei infection is due to a combination of (i) trypanosome-
released macrophage-activating factors leading to secretion of 
immunosuppressive factors such as NO, prostaglandins, and 
TNF and (ii) host-derived IFN-γ needed for optimal macrophage 
activation (110, 111). Moreover, this work also showed that 
within the T. brucei model, there is a compartmentalization of 
the suppressive effect in murine models during the later stages of 
infection, whereby NO plays a key role in macrophage-mediated 
splenic suppression, whereas the macrophage-mediated lymph 
node suppression occurred in an IFN-γ-dependent manner 
(110). Hence, at this stage of infection, an IFN-γ-independent 
suppressive mechanism is elicited in the spleen, whereas in the 
lymph nodes, IFN-γ is required yet not sufficient to inhibit T cell 
proliferation. In this context, it was shown that the trypanosome 
suppression-inducing factor (TSIF) released by T. brucei during 
the course of infection induces TNF and NO secretion by clas-
sically activated macrophages (i.e., M1), which is a prerequisite 
for parasite control. However, at the same time, it blocks T-cell 
proliferation in a NO, IFN-γ, and cell contact-dependent manner 
as well as downregulates type-2 immune responses required to 
dampen M1-mediated pathogenicity (112). Moreover, TSIF was 
shown to be essential for parasite biology given that TSIF knock-
down parasites die within 2 days. In the T. congolense model, it was 
shown that besides IFN-γ, the anti-inflammatory cytokine IL-10 
also contributed to T-cell suppression (113). Finally, although 
both murine and bovine African trypanosomosis induce sup-
pression, it seems that NO does not play a role in the loss of T-cell 
proliferative function in the bovine trypanosomosis model and 
that, in contrast to the mouse model, the capacity of monocytes 
and macrophages to produce NO is actually downregulated in 
infected cattle (114). In summary, these results suggest that the 
T-cell suppression is multifactorial, tissue and infection stage 
dependent, and host/parasite dependent. However, T-cells are 
dispensable for parasite control, which was evidenced by the fact 
that mice lacking a functional T-cell compartment are as efficient 
as immune-competent animals in controlling trypanosome 
infection (86). These data indicate that T-cell-independent 
B-cell-mediated elimination is the driving factor implicated in 
controlling parasitemia. Nevertheless, T-cells play a key role in 
the development of African trypanosomosis-associated patho-
genicity, such as anemia (115).
Undermining B-Cell Functionality
Given that trypanosomes are extracellular parasites, it is not 
surprising that the host–parasite coevolution resulted in a subtle 
equilibrium between suppression of B-cell and Ab functionality 
and parasite persistence. Indeed, besides suppression of myeloid 
cells and T-cells, B-cells were also found to be negatively affected 
during the early stages of trypanosome infection. Accordingly, 
trypanosomes exert full control of the different types of host 
immune responses to establish chronic infection. In this context, 
in cattle, it was found that there are also differences in humoral 
responses between T. congolense-infected trypano-resistant 
(N’Dama) and trypanosusceptible Boran cattle, further high-
lighting the importance of the humoral immune response in 
parasitemia control (116). In the following section, the effect of 
African trypanosome infections at the level of the B-cell compart-
ment will be scrutinized.
In homeostatic conditions, B-cells develop from bone mar-
row (BM)-derived hematopoietic stem cells (HSCs) that initially 
differentiate into multipotent progenitor cells and subsequently 
into common lymphoid progenitor cells (117). Next, B-cell 
lymphopoiesis occurs through several developmental stages, 
such as pre-pro-B, pro-B, pre-B, and, finally immature B-cells, 
which is a highly regulated process with alternating phases of cell 
proliferation and differentiation (118, 119). During this process, 
these different B-cell subsets rearrange their immunoglobulin 
heavy-chain and light-chain gene loci and express different sur-
face markers that can be identified via flow cytometry (see 
Table 1; Figure 2, left panel). Within the BM, these B-cells also 
undergo a positive and negative selection procedure, whereby 
the B-cell receptor (BCR) plays a checkpoint role (120). If the 
BCRs do not bind their antigen, they stop their development, i.e., 
during positive selection, while during negative selection, bind-
ing of self-antigens to the BCR triggers either clonal deletion, 
receptor editing, anergy, or ignorance, resulting in central toler-
ance (121). At the last stage of differentiation within the BM, 
these immature B-cells exhibit a high IgM expression and low or 
no expression of the IgD maturation marker. To complete their 
FigURe 2 | FACS gating strategy to track B-cell alterations during infection within the bone marrow (BM) and spleen. BM (left panel): (A,B) In an FSC-A 
versus SSC-A plot, a life gate was selected followed by gating on singlets in an SSC-A versus SSC-W plot, respectively. (C,D) Following gating on 7AAD− cells and 
plotting in a B220 versus IgM allow identification of IgM+ and IgM− cells. (e,F) The IgM+ cells are plotted in a B220 versus CD43 plot to identify B220+CD43− cells 
and subsequently plotted in a CD93 versus CD19 to identify immature B-cells (CD93+CD19+). (g) The IgM− cells are plotted in a B220 versus CD43 plot to identify 
B220+CD43− cells and B220+CD43+ cells. (H) The B220+CD43− cells are plotted in a CD93 versus CD19 to identify pre B-cells (CD93+CD19+). (i) The B220+CD43+ 
cells are plotted in a CD93 versus CD19 to identify pro B-cells (CD93+CD19+) and pre-pro B-cells (CD93+CD19−). Spleen (right panel): (A,B) In an FSC-A versus 
SSC-A plot, a life gate was selected followed by gating on singlets in an SSC-A versus SSC-W plot, respectively. (C,D) Following gating on 7AAD− cells and plotting 
in a CD93 versus B220 allow identification of immature B-cells (CD93+B220+). (e) The CD93+B220− cells are subsequently plotted in a CD1d versus B220 plot to 
identify marginal zone B (MZB) cells (CD1d+B220+) and follicular B (FoB) cells (CD1d−B220+). It is important to mention that during infection, the expression levels of 
typical splenic B-cell subset markers can be modulated, which substantially complicates the identification of the different B-lymphocyte subsets.
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development, immature B  cells migrate to the spleen via the 
blood as transitional B cells (T1 type). In the spleen, these tran-
sitional B (T1) cells differentiate into T2 cells before they develop 
into two types of mature naïve B-cells (122), namely follicular 
B  (FoB) or marginal zone B  (MZB) cells (see Figure  2, right 
panel). In homeostatic conditions, B  (FoB)  cells are mainly 
located in the white pulp area of the spleen where they form 
primary B-cell follicles, preferentially undergo T-cell-dependent 
activation (upon activation via proteins and glycoproteins), and 
can give rise to both short-lived plasma cells (i.e. plasmablasts) 
for immediate protection and high-affinity class-switched IgG 
long-lived plasma cells and memory B cells for persistent protec-
tion. In contrast, MZB cells are concentrated outside the splenic 
marginal sinus surrounding the white pulp. Most of the time, 
they initiate a fast and preferentially T-cell-independent 
activation (upon activation via polysaccharides or unmethylated 
CpG DNA) giving rise to not only short-lived plasma cells that 
rapidly produce low-affinity Abs of IgM isotype but also some 
populations of long-lived plasma cells (123). Overall, B-cell 
activation is considered a very efficient defense system against 
invading “extracellular/blood-borne” pathogens. However, 
African trypanosomes have developed efficient ways to under-
mine the host’s humoral response to establish chronic infection 
and allow completion of its life cycle/transmission. Indeed, using 
murine models, it was shown that African trypanosomes (both 
T. brucei and T. congolense) already during the early stages of 
infection trigger polyclonal B-cell activation in an attempt to 
dilute-out VSG-specific Abs during the course of infection. For 
example, it was shown that the CpG motifs of the T. brucei trypa-
nosomal genomic DNA triggers TLR-9 signaling events and 
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contributes to polyclonal B-cell activation (96). This phenomenon 
might contribute to parasite immune evasion by driving unselec-
tive differentiation of B  cells into short-lived plasma cells. In 
addition, Fcγ-receptors on phagocytes become saturated by poly-
specific Abs, thereby reducing the efficiency of opsonization-
mediated parasite clearance. Besides polyclonal B-cell activation, 
trypanosomes also undermine the “protective” humoral response 
by ablating B  cell lymphopoiesis in primary and secondary 
lymphoid organs during both T. brucei and T. congolense infec-
tions. This was reflected by a depletion of all developmental 
B-cell stages in the BM and the spleen as well as previous effector 
B cells, such as memory B cells (124–126), thereby preventing 
the development of a B-cell memory required for permanent 
elimination (Figure  3). Similar results were obtained in the 
experimental T. vivax model (127). In addition, experimental 
results obtained in mice and livestock animals have shown that 
trypanosome infections exert detrimental effects on non- 
pathogen-related vaccines, by preventing the occurrence of 
memory recall responses (126, 128–130), or on the maintenance 
of the antigen-specific plasma B cell pool driving the develop-
ment of collagen-induced arthritis (CIA) in DBA/1 prone mice 
(131). This destruction of the B-cell compartment at the level of 
both the BM and the spleen could be attributed to either parasite-
derived components and/or host-derived (infection-induced) 
components. Interestingly, a recent work by Cnops et al. (132), 
revealed that during murine infection with a chronic low-virulent 
T. b. gambiense field isolate, FoB cells are retained, which coin-
cided with reduced production of TNF and IFN-γ pro- 
inflammatory cytokines during the acute stage of infection 
compared to T. brucei and T. congolense infections. This finding 
was paralleled by the finding of Lejon et al. (133), which showed 
that in T. b. gambiense, HAT patients’ low parasite levels seem to 
be associated with limited B  cell dysfunction, whereby B-cell 
memory responses are only slightly reduced; however, the func-
tionality of these memory B cells was not verified in rechallenge 
studies. These findings indicate that in both experimental trypa-
nosomosis and natural infection, the inflammation stage linked 
to the acuteness of infection could be a major determinant in the 
FigURe 3 | Model for African trypanosomosis-associated impaired B-cell lymphopoiesis and improved vaccine development. (1) During the course of 
African trypanosomosis (AT), parasite-derived components are released that trigger besides polyclonal B-cell activation also the production of host-derived 
pro-inflammatory factors (i.e., NK-, NKT-, and T-cell-derived IFN-γ, M1-cell-derived TNF, NO, MIF) needed directly/indirectly for early parasite control. Yet, following 
control of the first parasitemia peak, polyclonal B-cell activation leads to dilution of parasite-specific antibodies, whereas the persistent pro-inflammatory response 
contributes to suppression of host responses and pathology. (2) Both parasite- and host-derived components can lead to a general state of impaired B-cell 
lymphopoiesis in (i) the bone marrow (BM), ranging from pre-pro-B-cell, pro-B-cell, pre-B-cell, and immature B-cell and (ii) the spleen, ranging from immature B-cell 
till MZB cell and FoB cell. In addition, also host-derived factors (involving M1) can contribute to T-cell suppression that in turn can affect B-cell homeostasis. (3) 
Hence, a more efficient therapeutic intervention strategy for AT should consist of a combination of (i) more reliable/sensitive diagnosis systems allowing early-stage 
parasite detection, (ii) more efficient trypanocidal/toxic drugs allowing improved parasite treatment, and (iii) pro-inflammatory-blocking molecules that could lead to a 
reduced pathology and a restoration of normal B-cell responses, thereby allowing more efficient/optimal vaccination. M1, classically activated myeloid cells; MIF, 
macrophage migration inhibitory factor; IFN, interferon; TNF, tumor necrosis factor; NO, nitric oxide; MZB, marginal zone B; FoB, follicular B.
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processes that drive B-cell compartment destruction. This 
hypothesis is reinforced by the fact that both IFN-γ(−/−) and IFN-
γR(−/−) mice are protected from early trypanosomosis-associated 
FoB cell depletion (134). This phenotype coincided with a drastic 
inhibition of B-cell apoptosis and a reduced activation of 
FoB  cells and inflammatory responses during the first week 
postinfection. These data demonstrated that IFN-γ is an impor-
tant cytokine involved in undermining trypanosomosis- 
associated B-cell responses. So far, the cellular source of early 
IFN-γ production involved in triggering impaired B-cell lym-
phopoiesis remains to be fully elucidated. However, it was 
recently suggested that NK-cells, an important early source of 
IFN-γ, are involved in B-cell killing and suppressing humoral 
immunity within the T. brucei model (115, 135). Yet, it cannot be 
excluded that other sources of IFN-γ, such as NKT, CD8+, and 
CD4+ T-cells, are also involved in IFN-γ-mediated B-cell apop-
tosis given that there is a transition of IFN-γ production by these 
cells during the course of T. brucei infection (115). Interestingly, 
upon drug treatment [suramin and diminazene aceturate 
(Berenil)] of T. brucei- and T. congolense-infected mice, the BM 
B-cell lymphopoiesis is reinitiated, and the splenic B-cell subsets 
are repopulated, suggesting that an active chronic infection (i.e., 
parasite–host interaction) is involved in undermining the 
humoral responses via either parasite-released components and/
or inflammatory-based mechanism(s) (136, 137). However, 
Uzonna and coworkers (137) showed that Berenil besides exert-
ing trypanolytic effects could also modulate the host immune 
response to the parasite by dampening excessive immune activa-
tion and production of pathology-promoting pro-inflammatory 
cytokines. Hence, it cannot be excluded that the beneficial effects 
of Berenil for treatment of AT are multifactorial: (i) eliminate 
parasites thereby resulting in reduced triggering of host inflam-
matory immune responses and (i) reduce the host’s pro-inflam-
matory potential to respond to pro-inflammatory/
parasite-derived components. In both cases, this will result in a 
more efficient host-mediated parasite control due to a recovery 
from the impaired B-cell lymphopoiesis and protection from 
infection-associated pathogenicity due to lower inflammatory 
responses (138). In this context, it was recently shown within the 
T. congolense experimental model that also host molecules such 
as macrophage migration inhibitory factor (MIF) can play a key 
role in regulating trypanosomosis-associated pro-inflammatory 
responses and B-cell homeostasis (139). In this work, it was 
shown that T. congolense-infected MIF-deficient mice exhibited 
increased Ab titers that correlated with reduced B-cell apoptosis. 
Hence, MIF could be considered as a target to alleviate the 
impaired B-cell lymphopoiesis.
CONCLUSiONS AND PeRSPeCTiveS
The extracellular African trypanosomes have acquired efficient 
immune evasion mechanisms to undermine protective host 
immune responses and allow survival in the host’s extracel-
lular environment. Hereby, they are proficient in avoiding 
elimination via the host’s humoral immune response by 
destroying the B-cell compartment/memory and shielding-
off conserved epitope, thereby paving the way for chronic 
infection. This destruction of B-cell memory already very 
early during infection might explain the failure of developing 
an effective vaccine. Indeed, immunization with the immuno-
dominant VSG did not yield any universal protection. So far, 
attempts to immunize with trypanosome molecules (VSG, 
beta tubulin, etc.), such as conserved membrane proteins 
or receptors for uptake of nutrients, have resulted in limited 
protective effects because such molecules are either concealed 
beneath the surface coat or are expressed at a to low level 
to induce protective host immunity (140, 141). However, 
some protection against AT-associated pathological features 
(i.e., anemia, tissue injury) has been achieved upon vaccina-
tion with pathology-inducing factors such as the VSG-derived 
GPI moiety (T. brucei, T. congolense) or the cysteine proteinase 
congopain (T. congolense), yet the animals were never fully 
cured (142, 143). Moreover, as far as the GPI-based strategy in 
the murine model was concerned, there was no effect on para-
sitemia but rather the protective effect correlated with reduced 
pro-inflammatory immune responses and was independent 
of the Ab response. This is in line with the observation that 
pathogenicity did not correlate with Ab levels at least for the 
experimental murine T. brucei model (86). In contrast, for the 
congopain vaccination strategy in experimental bovine T. con-
golense models, there was a correlation between reduced patho-
genicity and increased Ab titers (143, 144). This is in line with the 
observation that T. congolense-infected N’Dama cattle (a tryp-
anotolerant breed showing natural resistance to trypanosomo-
sis) exhibited higher antiparasite Ab titers than the susceptible 
Boran breeds (145, 146), suggesting that there are differences in 
the frequency of trypanosome-specific Ab-secreting cells in the 
spleen and in the activation state of B-cells in the blood between 
both cattle breeds during infection. Interestingly, the sera from 
T. congolense-infected N’Dama cattle specifically recognized 
dimer-associated epitopes on the congopain antigen (147).
The current research on vaccine development has switched 
toward identification of invariant surface glycoproteins or 
conserved c-terminal VSG epitopes/peptides that are pre-
dicted to contain several MHC II recognition sites (148–150). 
Whether these latter approaches will lead to the development 
of an effective protective and antipathology vaccine will be 
challenging and possibly not achievable given that African 
trypanosomes undermine B-cell memory responses. In addi-
tion, also the whole genome transcriptome analysis (i.e., SAGE 
technique) that enables to (i) explore the full transcriptome 
of trypanosusceptible and trypanotolerant cattle might lead 
to the identification of interesting gene variations linked to 
the trypanotolerance status of the animal (151–153) and (ii) 
understand the molecular aspects of the trypanosome dialog 
with its tsetse and mammalian hosts (i.e., interaction with the 
salivary glands and LS versus SS differentiation, respectively) 
might pave the way to develop novel diagnostic/therapeutic 
intervention strategies (154, 155). Furthermore, although the 
loss of B-cell responses/memory during AT might rely on either 
a parasite-induced or a host-induced effect or a combination 
of both, understanding the molecular mechanisms used by 
the trypanosomes to dampen B  cell responses might lead to 
the development of new therapeutics not only for AT but also 
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for other diseases such as autoimmune diseases (i.e., CIA) or 
malaria, where B-cell dysfunction is contributing to the disease 
outcome (131, 156–158). In this context, it was shown that the 
B-cell adaptor molecule Bam32 plays a pivotal role in optimal 
Ab responses and resistance during T. congolense infections 
in mice (159). Besides parasite-derived molecules, also host-
derived molecule could be considered as a potential target for 
intervention strategies. In this context, MIF can be proposed as 
potential candidate given that it can play a role both in innate 
as adaptive immunity via interaction with its main receptor 
CD74 to regulate the host inflammatory response (160, 161). 
Indeed, MIF was shown to play a pivotal role in stimulating/
inflammatory responses and regulating T- and B-cell recruit-
ment as well as B-cell proliferation/survival and thereby con-
tribute to pathology development (162–164). Hence, blocking 
MIF-signaling could reduce inflammatory responses, thereby 
alleviating suppression of B-cell lymphopoiesis, which in turn 
might favor vaccine efficacy.
In the future, most likely, a combination of (i) more sensitive/
reliable diagnosis techniques needed for early-stage parasite 
detection and (ii) anti-parasite intervention strategies (tryp-
anocidal/trypanotoxic drugs) and (iii) antidisease/pathology 
(anti-inflammatory) intervention strategies will be required to 
combat AT (see Figure 3).
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